For research use only. Not for human or veterinary use. Supplied as a lyophilized powder for laboratory research.
BPC-157 research spans more than three decades, but almost all of it is preclinical. BPC-157 (“Body Protection Compound-157”) is a synthetic 15-amino-acid peptide, GEPPPGKPADDAGLV, derived from a protein fragment found in human gastric juice [1][2]. A 2025 systematic review of BPC-157 studies included 36 studies, 35 of them preclinical [3]. A 2026 systematic review of human data found three small studies with 30 participants in total and rated the certainty of evidence very low [4]. BPC-157 is not FDA-approved for any use [1][3].
What is BPC-157? Sequence and structure
| Property | Value |
|---|---|
| BPC-157 sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV) [2] |
| Length | 15 residues (pentadecapeptide) [1] |
| Molecular formula | C₆₂H₉₈N₁₆O₂₂ (PubChem CID 108101) |
| Molecular weight | ~1419.5 g/mol (PubChem CID 108101) |
| CAS (as listed on the MFP certificate) | 137525-51-0 |
| Form supplied by MFP | Supplied as a lyophilized powder for laboratory research |
Origin of BPC-157
BPC-157 is described as a partial sequence of “body protection compound”, a substance isolated from human gastric juice [5]. A 2026 pharmaceutics review notes the peptide’s unusual stability in gastric juice [2].
Mechanisms studied in BPC-157 research
Reviews of the preclinical literature report these pathways in cell and animal models:
- Angiogenesis-related signaling: BPC-157 has been studied alongside standard angiogenic growth factors (EGF, FGF, VEGF) in gastrointestinal and tendon, ligament, muscle and bone models [6]. Another review describes VEGFR2 and nitric-oxide signaling through the Akt–eNOS axis, plus ERK1/2 [7].
- Fibroblast behavior: in rat Achilles tendon fibroblasts, BPC-157 increased explant outgrowth, cell survival under H₂O₂ stress and migration, without directly changing proliferation, linked to FAK–paxillin activation [5].
- Growth-hormone receptor expression and inflammatory cytokines, reported across the musculoskeletal preclinical studies in the 2025 systematic review [3].
These are findings from experimental models and do not establish effects in people.
BPC-157 studies by model type
| Evidence type | What the literature contains | Key limitation |
|---|---|---|
| In vitro | Tendon fibroblast outgrowth, survival and migration [5] | Cell systems only |
| Animal (mostly rodent) | Muscle, tendon, ligament, bone and gastrointestinal models [3][6] | Relevance to people not established [3][4] |
| Pharmacokinetics | Preclinical plasma half-life under 30 minutes; hepatic metabolism, renal clearance [2][3] | Human pharmacokinetics poorly characterized [2] |
| Human | 3 small studies, n = 30 total; poor methodological quality; certainty very low [4] | No controlled trials; no completed Phase II trial [2] |
BPC-157 clinical trials and regulatory status
- FDA: not approved for any indication [1][3]. A 2026 review notes there is no approved formulation and no validated regimen [2]. FDA also lists BPC-157 in Category 2 of bulk drug substances nominated for compounding, meaning substances that may present significant safety risks [8].
- Clinical trials: no completed Phase II trial has been reported [2].
- Anti-doping: published reviews describe its status differently. One reports a temporary WADA listing in 2022 and says it is not currently listed [1]; another describes it as banned in professional sports [3]. Check the current WADA Prohibited List directly.
MFP analytical data for BPC-157
| Field | Lot DPS-9628420 |
|---|---|
| Testing laboratory | Horizon Analytical (report no. 1023760) |
| Method | UPLC/MS |
| Purity | 99.42% (specification >98%) |
| Quantity | 9.9 mg (specification 10 mg) |
| Endotoxin | <0.05 EU/mL, Pass |
| Analysis date | 08/12/2026 |
Frequently asked questions
BPC-157 is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV) derived from a gastric-juice protein fragment and studied mainly in preclinical models [1][2].
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, abbreviated GEPPPGKPADDAGLV [2].
Human data are limited to three small studies rated very low certainty, and no completed Phase II trial has been reported [2][4].
No. It is not approved for any indication [1][3].
Research materials and certificates
- Research material: BPC-157, lyophilized powder · BPC-157 + TB-500 Bundle
- Certificates: COA Library
- Related: BPC-157 vs TB-500 (Thymosin Beta-4) · How to Read a Peptide COA · Lyophilized Peptide Storage
References
- Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. doi:10.3390/ph18020185. PMID: 40005999
- Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5):625. doi:10.3390/pharmaceutics18050625. PMID: 42198317
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. doi:10.1177/15563316251355551. PMID: 40756949
- Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026;92(3). doi:10.52628/92.3.15837. PMID: 42885452
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-80. doi:10.1152/japplphysiol.00945.2010. PMID: 21030672
- Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018;24(18):1972-1989. doi:10.2174/1381612824666180712110447. PMID: 29998800
- McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. doi:10.1007/s12178-025-09990-7. PMID: 40789979
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2). Content current as of 04/22/2026. fda.gov
Research-use-only disclaimer: All products from My Freedom Peptides are supplied as a lyophilized powder for laboratory research. They are for research use only and not for human or veterinary use. My Freedom Peptides LLC is a chemical supplier. It is not a 503A compounding pharmacy or a 503B outsourcing facility. These statements have not been evaluated by the Food and Drug Administration. Products are not intended to diagnose, treat, cure, or prevent any disease.
